Risk Factors and Predictive Nomogram for Survival in Elderly Patients with Brain Glioma

Abstract

Objective

To determine the factors that contribute to the survival of elderly individuals diagnosed with brain glioma and develop a prognostic nomogram.

Methods

Data from elderly individuals (age ≥65 years) histologically diagnosed with brain glioma were sourced from the Surveillance, Epidemiology, and End Results (SEER) database. The dataset was randomly divided into a training cohort and an internal validation cohort at a 6:4 ratio. Additionally, data obtained from Tangdu Hospital constituted an external validation cohort for the study. The identification of independent prognostic factors was achieved through the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis, enabling the construction of a nomogram. Model performance was evaluated using C-index, ROC curves, calibration plot and decision curve analysis (DCA).

Results

A cohort of 20 483 elderly glioma patients was selected from the SEER database. Five prognostic factors (age, marital status, histological type, stage, and treatment) were found to significantly impact overall survival (OS) and cancer-specific survival (CSS), with tumor location emerging as a sixth variable independently linked to CSS. Subsequently, nomogram models were developed to predict the probabilities of survival at 6, 12, and 24 months. The assessment findings from the validation queue indicate a that the model exhibited strong performance.

Conclusion

Our nomograms serve as valuable prognostic tools for assessing the survival probability of elderly glioma patients. They can potentially assist in risk stratification and clinical decision-making.

References

[1] RicardD, IdbaihA, DucrayF, et al.. Primary brain tumours in adults. Lancet, 2012, 379(9830): 1984-1996

[2] OstromQT, CioffiG, GittlemanH, et al.. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro-Oncology, 2019, 21(Supplement_5): v1-v100

[3] OstromQT, CioffiG, WaiteK, et al.. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncology, 2021, 23(Supplement_3): iii1-iii105

[4] OstromQT, PriceM, NeffC, et al.. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020. Neuro-Oncology, 2023, 25(Supplement_4): iv1-iv99

[5] PerryJR, LaperriereN, O’CallaghanC J, et al.. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med, 2017, 376(11): 1027-1037

[6] MaW, ShengX, LiG, et al.. Effectiveness of different treatment strategies in elderly patients with glioblastoma: An evidence map of randomized controlled trials. Crit Rev Oncol Hematol, 2022, 173: 103645

[7] HoffeS, BalducciL. Cancer and Age: General Considerations. Clin Geriatr Med, 2012, 28(1): 1-18

[8] TuranZG, ParviziP, DönertaşHM, et al.. Molecular footprint of Medawar’s mutation accumulation process in mammalian aging. Aging Cell, 2019, 18(4): e12965

[9] LiS, VazquezJM, SudmantPH. The evolution of aging and lifespan. Trends Genet, 2023, 39(11): 830-843

[10] ChoudhuryS, HuangAY, KimJ, et al.. Somatic mutations in single human cardiomyocytes reveal age-associated DNA damage and widespread oxidative genotoxicity. Nat Aging, 2022, 2(8): 714-725

[11] LiuZ, LiangQ, RenY, et al.. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther, 2023, 8(1): 200

[12] ZhaoW, GuoS, XuZ, et al.. Nomogram for Predicting Central Nervous System Infection Following Traumatic Brain Injury in the Elderly. World Neurosurg, 2024, 183: e28-e43

[13] IwamotoFM, ReinerAS, PanageasKS, et al.. Patterns of care in elderly glioblastoma patients. Ann Neurol, 2010, 64(6): 628-634

[14] SasakiH, KitamuraY, TodaM, et al.. Ctni-45. Upfront Chemotherapy and Subsequent Resection Utilizing Neoadjuvant Strategy For Oligodendrogliomas. Neuro Oncol, 2023, 25(Supplement_5): v85-v85

[15] KruchkoC, OstromQT, GittlemanH, et al.. The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol, 2018, 20(3): 295-298

[16] van den BentMJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol, 2014, 16(12): 1570-1574

[17] CoteDJ, OstromQT, GittlemanH, et al.. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer, 2019, 125(19): 3390-3400

[18] StabelliniN, KrebsH, PatilN, et al.. Sex Differences in Time to Treat and Outcomes for Gliomas. Front Oncol, 2021, 11: 630579

[19] NiuX, ChangT, YangY, et al.. Prognostic nomogram models for predicting survival probability in elderly glioblastoma patients. J Cancer Res Clin Oncol, 2023, 149(15): 14145-14157

[20] LiuZY, FengSS, ZhangYH, et al.. Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma. Sci Rep, 2021, 11(1): 9321

[21] JiaZ, YanY, WangJ, et al.. Development and validation of prognostic nomogram in ependymoma: A retrospective analysis of the SEER database. Cancer Med, 2021, 10(17): 6140-6148

[22] Furst T, Hoffman H, Chin LS. All-cause and tumor-specific mortality trends in geriatric oligodendroglioma (OG) patients: A surveillance, epidemiology, and end results (SEER) analysis. J Clin Neurosci, 2020,7394-100

[23] LiJ, HuangW, ChenJ, et al.. Nomograms for predicting the overall survival of patients with cerebellar glioma: an analysis of the surveillance epidemiology and end results (SEER) database. Sci Rep, 2021, 11(1): 19348

[24] WenJ, ChenW, ZhuY, et al.. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. BMC Cancer, 2021, 21(1): 81

[25] CaoJ, YanW, ZhanZ, et al.. Epidemiology and risk stratification of low-grade gliomas in the United States, 2004–2019: A competing-risk regression model for survival analysis. Front Oncol, 2023, 13: 1079597

[26] LiuJ, LiC, WangY, et al.. Prognostic and Predictive Factors in Elderly Patients With Glioblastoma: A Single-Center Retrospective Study. Front Aging Neurosci, 2022, 13: 777962

[27] DollKM, RademakerA, SosaJA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg, 2018, 153(6): 588-589

[28] ZhangX, ChangL, ZhuY, et al.. Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution. Front Endocrinol (Lausanne), 2023, 14: 1139222

[29] LouisDN, OhgakiH, WiestlerOD, et al.. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol, 2007, 114(2): 97-109

[30] MalhotraAK, KarthikeyanV, ZabihV, et al.. Adolescent and young adult glioma: systematic review of demographic, disease, and treatment influences on survival. Neurooncol Adv, 2022, 4(1): 4(1):vdac168

[31] ZhengC, BergerNA, LiL, et al.. Epigenetic age acceleration and clinical outcomes in gliomas. PLoS One, 2020, 15(7): e0236045

[32] BauchetL, ZouaouiS, DarlixA, et al.. Assessment and treatment relevance in elderly glioblastoma patients. Neuro Oncol, 2014, 16(11): 1459-1468

[33] GlantzM, ChamberlainM, LiuQ, et al.. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer, 2003, 97(9): 2262-2266

[34] ZhuY, LiC, XieW, et al.. Trajectories of depressive symptoms and subsequent cognitive decline in older adults: a pooled analysis of two longitudinal cohorts. Age Ageing, 2021, 51(1): afab191

[35] BerkM, Köhler-ForsbergO, TurnerM, et al.. Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World Psychiatry, 2023, 22(3): 366-387

[36] KimYJ, LeeDJ, ParkCK, et al.. Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era. Neurosurg Rev, 2019, 42(4): 937-950

[37] BabuR, KomisarowJM, AgarwalVJ, et al.. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg, 2016, 124(4): 998-1007

[38] ZhaoB, WuJ, XiaY, et al.. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. Pharmacol Res, 2022, 182: 106316

[39] RehmanSK, HaynesJ, CollignonE, et al.. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell, 2021, 184(1): 226-242.e21

[40] PetroniG, CantleyLC, SantambrogioL, et al.. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat Rev Clin Oncol, 2022, 19(2): 114-131

[41] YangM, ZhangZ, NiceEC, et al.. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer, 2022, 1877(1): 188665

[42] HeXY, GaoY, NgD, et al.. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell, 2024, 42(3): 474-486.e12